Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2010

01-05-2010 | Original paper

Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma

Authors: Pia Fernberg, Ellen T. Chang, Kristina Duvefelt, Henrik Hjalgrim, Sandra Eloranta, Karina Meden Sørensen, Anna Porwit, Keith Humphreys, Mads Melbye, Karin Ekström Smedby

Published in: Cancer Causes & Control | Issue 5/2010

Login to get access

Abstract

Background

Tumor necrosis factor (TNF) and interleukin 10 (IL10) are promising candidate susceptibility genes for non-Hodgkin lymphoma (NHL). Chromosomal translocation breakpoint genes are of interest, given their documented involvement in lymphoma progression.

Methods

We analyzed 11 polymorphisms in BCL2, CCND1, MYC, TNF, and IL10 in a large, population-based, Danish-Swedish case–control study including 2,449 NHL cases and 1,980 controls. Relative risk of NHL was computed as odds ratios (OR).

Results

There was no clear evidence of associations between variants in BCL2, CCND1, and MYC and risk of NHL overall or subtypes. TNF rs1800629 was associated with risk of NHL (OR 1.53, 95% confidence interval, CI, 1.06–2.19 for minor allele homozygosity), T-cell lymphoma (OR 2.54, CI 1.27–5.09) and mantle cell lymphoma (OR 2.84, CI 1.38–5.87). IL10 rs1800890 was associated with risk of diffuse large B-cell lymphoma (OR 1.41, CI 1.08–1.85 for minor allele homozygosity) and mantle cell lymphoma (OR 1.77, CI 1.04–3.00). We did not replicate a previously reported interaction with autoimmunity.

Conclusions

We found no support for a role of the studied variants in BCL2, CCND1, or MYC in risk of NHL or subtypes, but we provide further evidence of putative susceptibility loci in TNF and IL10 for specific NHL subtypes.
Literature
1.
Alexander DD, Mink PJ, Adami HO et al (2007) The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120(Suppl 12):1–39CrossRefPubMed
2.
Ekstrom-Smedby K (2006) Epidemiology and etiology of non-Hodgkin lymphoma—a review. Acta Oncol 45:258–271CrossRefPubMed
3.
Zhu K, Levine RS, Gu Y et al (1998) Non-Hodgkin’s lymphoma and family history of malignant tumors in a case-control study (United States). Cancer Causes Control 9:77–82CrossRefPubMed
4.
Goldin LR, Pfeiffer RM, Gridley G et al (2004) Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 100:1902–1908CrossRefPubMed
5.
Skibola CF, Curry JD, Nieters A (2007) Genetic susceptibility to lymphoma. Haematologica 92:960–969CrossRefPubMed
6.
Skibola CF, Bracci PM, Halperin E et al (2008) Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS ONE 3:e2816CrossRefPubMed
7.
Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38CrossRefPubMed
8.
Wang SS, Cozen W, Cerhan JR et al (2007) Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 67:5042–5054CrossRefPubMed
9.
Bel Hadj Jrad B, Chatti A, Laatiri A et al (2007) Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin’s lymphomas. Eur J Haematol 78:117–122PubMed
10.
Purdue MP, Lan Q, Kricker A et al (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28:704–712CrossRefPubMed
11.
Wang SS, Cerhan JR, Hartge P et al (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 66:9771–9780CrossRefPubMed
12.
Spink CF, Keen LJ, Mensah FK et al (2006) Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 133:293–300CrossRefPubMed
13.
Wang SS, Purdue MP, Cerhan JR et al (2009) Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS ONE 4:e5360CrossRefPubMed
14.
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759CrossRefPubMed
15.
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765CrossRefPubMed
16.
Jaffe ES HN, Stein H, Vardiman JW editors (2001) WHO classification of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues, Lyon, France. International Agency for Research on Cancer Press
17.
Iqbal J, Sanger WG, Horsman DE et al (2004) BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 165:159–166PubMed
18.
Huang JZ, Sanger WG, Greiner TC et al (2002) The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285–2290CrossRefPubMed
19.
Kodet R, Mrhalova M, Krskova L et al (2003) Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Arch 442:538–547PubMed
20.
Kawasaki C, Ohshim K, Suzumiya J et al (2001) Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma 42:1099–1106CrossRefPubMed
21.
Leder P, Battey J, Lenoir G et al (1983) Translocations among antibody genes in human cancer. Science 222:765–771CrossRefPubMed
22.
Wang SS, Cozen W, Severson RK et al (2006) Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet 120:297–300CrossRefPubMed
23.
Zhang Y, Lan Q, Rothman N et al (2005) A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. J Natl Cancer Inst 97:1616–1618PubMed
24.
Morton LM, Purdue MP, Zheng T et al (2009) Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 18:1259–1270CrossRefPubMed
25.
Cleary ML, Galili N, Sklar J (1986) Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 164:315–320CrossRefPubMed
26.
Tsujimoto Y, Jaffe E, Cossman J et al (1985) Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315:340–343CrossRefPubMed
27.
de Jong D (2005) Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 23:6358–6363CrossRefPubMed
28.
Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80:879–886PubMed
29.
Butler M, Corbally N, Dervan PA, Carney DN (1997) BCL-6 and other genomic alterations in non-Hodgkin’s lymphoma (NHL). Br J Cancer 75:1641–1645PubMed
30.
Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442CrossRefPubMed
31.
Dreyling MH, Bullinger L, Ott G et al (1997) Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57:4608–4614PubMed
32.
Smedby KE, Askling J, Mariette X, Baecklund E (2008) Autoimmune and inflammatory disorders and risk of malignant lymphomas—an update. J Intern Med 264:514–527CrossRefPubMed
33.
Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701CrossRefPubMed
34.
Smedby KE, Hjalgrim H, Melbye M et al (2005) Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 97:199–209PubMedCrossRef
35.
d’Amore F, Christensen BE, Brincker H et al (1991) Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 27:1201–1208CrossRefPubMed
36.
Sorensen KM, Jespersgaard C, Vuust J et al (2007) Whole genome amplification on DNA from filter paper blood spot samples: an evaluation of selected systems. Genet Test 11:65–71CrossRefPubMed
37.
Milani L, Gupta M, Andersen M et al (2007) Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res 35:e34CrossRefPubMed
38.
Howe D, Lynas C (2001) The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 86:563–569PubMed
39.
Wirtenberger M, Hemminki K, Forsti A et al (2005) c-MYC Asn11Ser is associated with increased risk for familial breast cancer. Int J Cancer 117:638–642CrossRefPubMed
40.
Jurinke C, van den Boom D, Cantor CR, Koster H (2002) Automated genotyping using the DNA MassArray technology. Methods Mol Biol 187:179–192PubMed
41.
Phillips MS, Lawrence R, Sachidanandam R et al (2003) Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots. Nat Genet 33:382–387CrossRefPubMed
42.
43.
Smedby KE, Hjalgrim H, Askling J et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98:51–60PubMed
44.
Clayton D, Chapman J, Cooper J (2004) Use of unphased multilocus genotype data in indirect association studies. Genet Epidemiol 27:415–428CrossRefPubMed
45.
Westfall PH, Zaykin DV, Young SS (2002) Multiple tests for genetic effects in association studies. Methods Mol Biol 184:143–168PubMed
46.
Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442PubMedCrossRef
47.
Skibola CF, Nieters A, Bracci PM et al (2008) A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 111:4348–4354CrossRefPubMed
48.
Cerhan JR, Liu-Mares W, Fredericksen ZS et al (2008) Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev 17:3161–3169CrossRefPubMed
49.
Susova S, Trneny M, Soucek P (2006) Single nucleotide polymorphism in 5′-flanking region of BCL6 is not associated with increased risk of non-Hodgkin’s lymphoma. Cancer Lett 238:142–145CrossRefPubMed
Metadata
Title
Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma
Authors
Pia Fernberg
Ellen T. Chang
Kristina Duvefelt
Henrik Hjalgrim
Sandra Eloranta
Karina Meden Sørensen
Anna Porwit
Keith Humphreys
Mads Melbye
Karin Ekström Smedby
Publication date
01-05-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9504-y

Other articles of this Issue 5/2010

Cancer Causes & Control 5/2010 Go to the issue

Original paper

Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004

Original paper

Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort

Original paper

Birth weight, breast cancer susceptibility loci, and breast cancer risk

Original paper

Lifetime exposure to arsenic in drinking water and bladder cancer: a population-based case–control study in Michigan, USA

Original paper

Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers

Editorial

Ensuring long-term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits